Ixekizumab vs. Guselkumab for Moderate-to-severe Psoriasis Ixekizumab vs. Guselkumab for Moderate-to-severe Psoriasis

This study compared early and complete skin clearance in patients with moderate-to-severe plaque psoriasis by the IL-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab.The British Journal of Dermatology

Source: Medscape Today Headlines - July 17, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news